Scope, Claims, and U.S. Patent Landscape for US Drug Patent 12,396,947 (Methotrexate Oral Solution)
What is the claim scope of US 12,396,947?
US 12,396,947 claims a methotrexate oral composition in a specific formulation state: an aqueous solution with controlled pH (6 to 7) using buffer agents, with preserving agents, and with taste-masking excipients (flavouring compounds and/or sweetening agents). The claim is composition-focused and functional only to the extent it ties ingredients to a pH range and to solution form.
Independent claim (as provided): Claim 1
- A methotrexate composition for oral administration, said composition consisting of:
- methotrexate or a salt thereof;
- one or more buffer agents to adjust the pH of the composition, wherein pH is 6 to 7;
- one or more preserving agents;
- one or more agents selected from flavouring compounds and sweetening agents; and
- purified water,
wherein the composition is a solution.
Core claim elements (scope map)
| Element |
Claim language |
Practical scope effect |
| Drug substance |
“methotrexate or a salt thereof” |
Covers methotrexate base and salt forms; claim is not restricted to a particular salt. |
| Intended use |
“for oral administration” |
Limits to products that are orally administered; does not cover parenteral formulations. |
| Dosage form/state |
“purified water” and “wherein the composition is a solution” |
Limits to aqueous solution (not suspensions, emulsions, lyophilizates, tablets, capsules). |
| pH control |
“one or more buffer agents… wherein pH… is 6 to 7” |
Hard numerical limitation; a formulation outside this range avoids the literal element. |
| Preservation |
“one or more preserving agents” |
Requires at least one preservative class agent, without specifying identity. |
| Palatability excipients |
“one or more agents selected from flavouring compounds and sweetening agents” |
Requires at least one of: flavouring and/or sweetening agents; does not require both. |
| Ingredient relationship |
“consisting of” |
Closed/limiting transition: the claim allows only the listed ingredient categories plus their conventional variants that still fall within the listed categories. Unlisted additional components risk non-infringement under a strict reading. |
How broad is “consisting of” in practice?
“Consisting of” is a closed formulation claim style. It typically means a product infringes only if it contains the recited elements, and it does not contain additional ingredients that fall outside the enumerated categories.
From a scope perspective, US 12,396,947 is broad in what it does not specify, but narrow in what it does specify:
- Broad because it does not name specific buffer/preservative/flavour/sweetener identities.
- Narrow because it requires solution form and a pH of 6 to 7, and it uses “consisting of” to limit the allowable excipient set.
A competitor attempting to avoid the claim has three primary literal design levers:
- move the formulation to pH outside 6 to 7;
- change the dosage form so it is not a solution;
- include components that would be characterized as additional and not captured within the listed excipient categories.
What are the claim’s likely infringement triggers?
Under a literal analysis, infringement would likely be triggered when all of these are true simultaneously:
- an aqueous oral methotrexate composition;
- pH adjusted into 6 to 7 using buffer agents;
- contains preserving agents;
- contains flavouring and/or sweetening agents;
- is a solution using purified water;
- contains “methotrexate or a salt thereof”.
Practical “all-elements” test
| Test item |
Must be satisfied |
| Drug identity |
methotrexate or salt |
| Route |
oral administration |
| Form |
solution |
| Vehicle |
purified water present in solution |
| pH |
6 to 7 (numerical) |
| Buffers |
at least one buffer agent used for pH adjustment |
| Preservatives |
at least one preserving agent present |
| Palatability |
at least one flavouring or sweetening agent present |
What claim types does this look like (composition vs. method)?
The claim is a composition claim. It does not claim:
- a manufacturing method;
- a dosing regimen;
- a process parameter (other than pH);
- a pharmacokinetic outcome;
- a specific stability or shelf-life metric.
This matters for landscape assessment because it concentrates enforceability around product formulation rather than manufacturing steps or clinical endpoints.
Where does US 12,396,947 sit within the methotrexate formulation landscape?
Methotrexate is a well-established oncology and autoimmune drug. The formulation landscape in the U.S. typically includes:
- solid oral dosage forms (tablets);
- injectable solutions;
- oral liquids used for pediatric or administration convenience.
US 12,396,947 is a targeted liquid oral solution claim centered on:
- aqueous solution;
- buffered pH 6 to 7;
- preservative system;
- taste-masking.
This is consistent with common formulation engineering goals for methotrexate oral liquids: maintain chemical stability in an acceptable pH window, ensure microbial control with preservatives, and address palatability.
What design-around strategies are suggested by the claim language?
Because the claim contains explicit numerical and structural limitations, design-around options are mostly formulation-level.
1) pH adjustment
The claim requires pH 6 to 7. A competitor can target:
If pH can be maintained during storage and at administration, the competitor can avoid a literal “pH 6 to 7” limitation.
2) dosage form shift away from “solution”
The claim says “wherein the composition is a solution.” If a product is formulated as:
- a suspension,
- an emulsion,
- a reconstituted powder,
then it may fall outside “solution” depending on how “solution” is interpreted under claim construction.
3) shift preservative or palatability structure
The claim does not specify preservative identity, only that “one or more preserving agents” are present. Avoidance is thus less likely by choosing a preservative system and more likely by:
- omitting preservatives (risky for practical shelf-life and compliance);
- using a different preservation strategy that is not characterized as a “preserving agent” under claim interpretation (fact-intensive).
Palatability: the claim requires “one or more agents selected from flavouring compounds and sweetening agents.” A competitor could attempt to omit flavouring and/or sweetening agents and use another approach (e.g., different delivery system). But direct omission of both classes would likely conflict with the claim’s explicit requirement.
4) “consisting of” constraints
Because the claim is “consisting of,” a competitor adding ingredients outside the listed categories can argue non-infringement. The key is how those added ingredients are characterized (is a given additive still a “buffer agent,” “preserving agent,” “flavouring,” or “sweetening,” or is it an additional excipient outside the enumerated list?).
What does the claim cover that could be commercially meaningful?
For licensing and freedom-to-operate screening, the value is that US 12,396,947 potentially reaches:
- oral methotrexate liquids;
- buffered aqueous solutions in a narrow pH window;
- products engineered for patient palatability and microbiological control.
Coverage bottleneck
The main commercial bottleneck is the combination of:
- solution form,
- pH 6 to 7,
- preservatives present,
- flavour/sweetener present.
A product that misses any of these may avoid literal infringement.
How strong is enforcement likely to be, and where are evidentiary pressures?
Because the claim is tight on composition parameters, enforcement hinges on what is in the product and its measured pH.
- pH: typically assessed by testing the product as formulated.
- ingredient presence: preservative and flavour/sweetener excipients must be identified.
- form: solution versus suspension is typically evident by product description and characterization.
- closed formulation (“consisting of”): requires claim construction and careful excipient mapping.
What is the U.S. patent landscape around this claim (strategic positioning)?
A complete U.S. landscape requires knowing the full patent family, assignee, filing dates, prosecution history, specification, and any related continuations or divisionals. Those details are not provided in the prompt. Without them, only the claim-driven landscape can be mapped.
Landscape partitions relevant to US 12,396,947
| Partition |
What to look for in the landscape |
Why it matters |
| Oral methotrexate solutions |
patents claiming buffered oral liquids, pH ranges, preservatives, palatability |
potential overlapping scope |
| Oral methotrexate suspensions |
pH control and preservatives in non-solution dosage forms |
may be safe from “solution” limitation |
| Taste-masked oral methotrexate compositions |
inclusion/exclusion of flavouring and sweetening |
claim requires these categories |
| Buffer/preservative selection patents |
excipient-specific patents |
may or may not be encompassed by “buffer/preserving agents” categories |
| Process claims |
manufacturing methods for oral liquids |
may avoid composition claim but still be relevant separately |
What to prioritize in an FTO search and clearance package
Even without family details, a claim-anchored clearance should prioritize:
-
Product characterization
- Is the commercial product an oral solution?
- What is the measured pH (during shelf-life and at use conditions)?
-
Ingredient mapping
- Identify whether it contains buffer agents and preserving agents.
- Confirm whether it includes flavouring and/or sweetening agents.
-
Closed-claim compliance
- Identify all excipients and evaluate whether any added components fall outside “buffer agents,” “preserving agents,” and “flavouring/sweetening” categories.
-
Potential claim overlaps
- Look for other methotrexate oral liquid patents with different pH ranges or different dosage form definitions.
Key Takeaways
- US 12,396,947 claims an oral aqueous methotrexate solution with pH 6 to 7, using buffer agents, containing preserving agents, and including flavouring and/or sweetening agents.
- The claim is closed via “consisting of,” which can limit infringement if additional excipients fall outside the enumerated categories.
- The strongest literal infringement trigger is the simultaneous presence of: solution form, buffered pH 6 to 7, preservatives, and flavour/sweetener excipients.
- The most direct design-around levers are moving pH outside 6 to 7 or changing the dosage form away from a solution.
FAQs
What does “solution” mean for infringement purposes?
It means the claimed composition is presented and characterized as a solution (not a suspension). The product must meet the claim’s dosage-form state.
Does the claim require both flavouring and sweetening agents?
No. It requires “one or more agents selected from flavouring compounds and sweetening agents,” which covers either class or both.
Are specific buffer or preservative identities required by the claim?
No. The claim requires buffer agents to adjust pH and preserving agents, but it does not specify which ones.
Can a methotrexate salt be used to meet the drug element?
Yes. The claim covers “methotrexate or a salt thereof.”
What is the single narrowest limitation in Claim 1?
The pH restriction: “wherein the pH of the composition is 6 to 7,” which is a hard numerical boundary.
References
[1] User-provided claim text for U.S. Drug Patent 12,396,947 (Claim 1: methotrexate oral solution with buffer-adjusted pH 6 to 7, preserving agents, flavouring/sweetening agents, purified water).
